Paul M. Moseley

1.6k total citations
45 papers, 1.1k citations indexed

About

Paul M. Moseley is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Paul M. Moseley has authored 45 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 25 papers in Molecular Biology and 14 papers in Cancer Research. Recurrent topics in Paul M. Moseley's work include DNA Repair Mechanisms (17 papers), Cancer-related Molecular Pathways (12 papers) and HER2/EGFR in Cancer Research (9 papers). Paul M. Moseley is often cited by papers focused on DNA Repair Mechanisms (17 papers), Cancer-related Molecular Pathways (12 papers) and HER2/EGFR in Cancer Research (9 papers). Paul M. Moseley collaborates with scholars based in United Kingdom, United States and Australia. Paul M. Moseley's co-authors include Stephen Chan, Ian O. Ellis, Srinivasan Madhusudan, Tarek M.A. Abdel-Fatah, Graham Ball, Emad A. Rakha, Andrew R. Green, Christina J. Perry, Arvind Arora and Devika Agarwal and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Paul M. Moseley

45 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul M. Moseley United Kingdom	22	796	616	314	116	112	45	1.1k
Swati Palit Deb United States	19	966 1.2×	1000 1.6×	313 1.0×	188 1.6×	87 0.8×	39	1.5k
Ahrum Min South Korea	16	634 0.8×	635 1.0×	123 0.4×	181 1.6×	78 0.7×	36	957
Ángel Guerrero‐Zotano Spain	12	735 0.9×	454 0.7×	445 1.4×	188 1.6×	73 0.7×	29	1.1k
Jeff C. Liu Canada	19	897 1.1×	660 1.1×	434 1.4×	197 1.7×	64 0.6×	25	1.4k
Pien M. Delis‐van Diemen Netherlands	20	660 0.8×	388 0.6×	295 0.9×	146 1.3×	196 1.8×	35	1.1k
Hans Kristian Moen Vollan Norway	18	705 0.9×	466 0.8×	573 1.8×	213 1.8×	97 0.9×	25	1.3k
Elena A. Takano Australia	19	795 1.0×	390 0.6×	337 1.1×	145 1.3×	68 0.6×	35	1.2k
Carles Barceló Spain	10	640 0.8×	616 1.0×	300 1.0×	136 1.2×	184 1.6×	17	1.2k
Anne‐Lise Børresen‐Dale Norway	15	822 1.0×	446 0.7×	527 1.7×	123 1.1×	84 0.8×	20	1.2k
Bose Kochupurakkal United States	16	1.0k 1.3×	810 1.3×	183 0.6×	169 1.5×	63 0.6×	44	1.4k

Countries citing papers authored by Paul M. Moseley

Since Specialization

Citations

This map shows the geographic impact of Paul M. Moseley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul M. Moseley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul M. Moseley more than expected).

Fields of papers citing papers by Paul M. Moseley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul M. Moseley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul M. Moseley. The network helps show where Paul M. Moseley may publish in the future.

Co-authorship network of co-authors of Paul M. Moseley

This figure shows the co-authorship network connecting the top 25 collaborators of Paul M. Moseley. A scholar is included among the top collaborators of Paul M. Moseley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul M. Moseley. Paul M. Moseley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Naidoo, Kuban D., Patty T. Wai, Sarah Maguire, et al.. (2018). Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response–Targeted Therapies in Breast Cancer. Molecular Cancer Therapeutics. 17(1). 306–315. 54 indexed citations

Machado, Lee R., Paul M. Moseley, Suha Deen, et al.. (2017). High mobility group protein B1 is a predictor of poor survival in ovarian cancer. Oncotarget. 8(60). 101215–101223. 11 indexed citations

Abdel-Fatah, Tarek M.A., Robert C. Rees, A. Graham Pockley, et al.. (2017). The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2. Oncotarget. 8(68). 112245–112257. 2 indexed citations

Abdel-Fatah, Tarek M.A., Stéphanie McArdle, Devika Agarwal, et al.. (2015). HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis. Clinical Cancer Research. 22(4). 905–914. 18 indexed citations

Arora, Arvind, Tarek M. Abdel-Fatah, Devika Agarwal, et al.. (2015). Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer. Molecular Cancer Therapeutics. 14(4). 1057–1065. 42 indexed citations

Alsubhi, Nouf H., Fiona K. Middleton, Tarek M.A. Abdel-Fatah, et al.. (2015). Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio‐resistance in breast cancer. Molecular Oncology. 10(2). 213–223. 30 indexed citations

Arora, Arvind, Devika Agarwal, Huiming Lu, et al.. (2015). RECQL4 helicase has oncogenic potential in sporadic breast cancers. The Journal of Pathology. 238(4). 495–501. 45 indexed citations

Pu, Xuan, Sarah J. Storr, Stephen Chan, et al.. (2015). Calpain‐1 is associated with adverse relapse free survival in breast cancer: a confirmatory study. Histopathology. 68(7). 1021–1029. 10 indexed citations

Barros, F., Tarek M.A. Abdel-Fatah, Paul M. Moseley, et al.. (2014). Characterisation of HER heterodimers in breast cancer using in situ proximity ligation assay. Breast Cancer Research and Treatment. 144(2). 273–285. 16 indexed citations

10.

Abdel-Fatah, Tarek M., Graham Ball, Andrew H.S. Lee, et al.. (2014). Nottingham Clinico-Pathological Response Index (NPRI) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer. Clinical Cancer Research. 21(5). 1052–1062. 14 indexed citations

11.

Abdel-Fatah, Tarek M.A., Christina J. Perry, Arvind Arora, et al.. (2014). Is There a Role for Base Excision Repair in Estrogen/Estrogen Receptor-Driven Breast Cancers?. Antioxidants and Redox Signaling. 21(16). 2262–2268. 25 indexed citations

12.

Abdel-Fatah, Tarek M.A., Fiona K. Middleton, Arvind Arora, et al.. (2014). Untangling the ATR‐CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer. Molecular Oncology. 9(3). 569–585. 71 indexed citations

13.

Abdel-Fatah, Tarek M., Arvind Arora, Nouf H. Alsubhi, et al.. (2014). Clinicopathological Significance of ATM-Chk2 Expression in Sporadic Breast Cancers: a Comprehensive Analysis in Large Cohorts. Neoplasia. 16(11). 982–991. 36 indexed citations

14.

Abdel-Fatah, Tarek M.A., Stéphanie McArdle, Catherine Johnson, et al.. (2014). HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer. British Journal of Cancer. 110(10). 2450–2461. 24 indexed citations

15.

Abdel-Fatah, Tarek M.A., Arvind Arora, Devika Agarwal, et al.. (2014). Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers. Breast Cancer Research and Treatment. 146(2). 309–320. 11 indexed citations

16.

Abdel-Fatah, Tarek M.A., Roslin Russell, Devika Agarwal, et al.. (2014). DNA polymerase β deficiency is linked to aggressive breast cancer: A comprehensive analysis of gene copy number, mRNA and protein expression in multiple cohorts. Molecular Oncology. 8(3). 520–532. 30 indexed citations

17.

Abdel-Fatah, Tarek M.A., Arvind Arora, Paul M. Moseley, et al.. (2014). ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers. PubMed. 2. 10–17. 48 indexed citations

18.

Sultana, Rebeka, Tarek M.A. Abdel-Fatah, Christina J. Perry, et al.. (2013). Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase Inhibition Is Synthetically Lethal in XRCC1 Deficient Ovarian Cancer Cells. PLoS ONE. 8(2). e57098–e57098. 65 indexed citations

19.

Abdel-Fatah, Tarek M., Nada Albarakati, Devika Agarwal, et al.. (2013). Single-strand selective monofunctional uracil-DNA glycosylase (SMUG1) deficiency is linked to aggressive breast cancer and predicts response to adjuvant therapy. Breast Cancer Research and Treatment. 142(3). 515–527. 31 indexed citations

20.

Perry, Christina J., P. Dickinson, Graham Ball, et al.. (2013). Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings. Annals of Oncology. 24(11). 2801–2807. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact